IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) updated its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 14.960-15.160 for the period, compared to the consensus estimate of 14.860. The company issued revenue guidance of $4.7 billion-$4.8 billion, compared to the consensus revenue estimate of $4.7 billion.
Wall Street Analyst Weigh In
A number of research analysts recently weighed in on the stock. Jefferies Financial Group decreased their price target on shares of IDEXX Laboratories from $795.00 to $705.00 and set a “buy” rating on the stock in a research note on Tuesday, October 20th. Weiss Ratings raised IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, October 8th. BTIG Research dropped coverage on IDEXX Laboratories in a research report on Friday. They set a “buy” rating for the company. UBS Group reissued a “neutral” rating and issued a $700.00 price objective (up from $627.00) on shares of IDEXX Laboratories in a research note on Tuesday. Finally, Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Eight research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $727.75.
View Our Latest Stock Analysis on IDXX
IDEXX Laboratories Trading Down 0.1%
Shares of IDXX traded down $0.44 during mid-day trading on Tuesday, reaching $671.20. The stock had a trading volume of 207,293 shares, compared to its average volume of 573,208. IDEXX Laboratories has a 52-week low of $500.61 and a 52-week high of $769.98. The firm has a market cap of $52.88 billion, a price-to-earnings ratio of 47.13 and a beta of 1.55. The business’s fifty day moving average is $536.56 and its 200 day moving average is $573.88. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.17 and a quick ratio of 0.87.
IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last issued its quarterly earnings data on Monday, November 2nd. The company reported $3.96 EPS for the quarter, topping the consensus estimate of $3.71 by $0.25. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The firm had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.19 billion. During the same period in the prior year, the business posted $3.22 EPS. The business’s revenue for the quarter was up 9.9% compared to the same quarter last year. On average, sell-side analysts predict that IDEXX Laboratories will post 14.81 EPS for the current fiscal year.
Insider Activity
In other IDEXX Laboratories news, Director Lawrence D. Kingsley sold 2,203 shares of the firm’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the transaction, the director directly owned 9,568 shares of the company’s stock, valued at approximately $5,090,941.44. This trade represents a 18.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 0.79% of the company’s stock.
Key Stories Impacting IDEXX Laboratories
Here are the key news stories impacting IDEXX Laboratories this week:
- Positive Sentiment: Q3 beat estimates: IDEXX reported adjusted EPS of approximately $3.96–$3.98, above the $3.71 consensus estimate, while revenue rose 9.9% year over year to about $1.21 billion, exceeding expectations of $1.19 billion. IDEXX Laboratories earnings report
- Positive Sentiment: Raised 2026 guidance: The company now expects full-year EPS of $14.96–$15.16, above the $14.86 analyst consensus, and revenue of $4.7–$4.8 billion, with the top end exceeding expectations. IDEXX raises forecast
- Positive Sentiment: Recurring diagnostics remained the growth engine: Diagnostics sales to veterinarians increased about 11%, supporting stronger revenue, earnings and investor expectations for continued execution. Morgan Stanley reiterated its Buy rating and maintained an $805 price target. Morgan Stanley reiterates Buy rating
- Neutral Sentiment: The earnings-driven rally was substantial, leaving IDXX near the upper portion of its recent trading range and potentially increasing the risk of profit-taking despite the improved fundamentals. IDEXX surges on Q3 beat
- Negative Sentiment: Margin and demand caveat: Reports indicated that the higher profit outlook was not primarily driven by stronger testing demand, while the margin outlook softened and veterinary visits remained weak. These factors could limit the durability of the rally. IDEXX sales rise as margin outlook slips
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.
IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.
Read More
- Five stocks we like better than IDEXX Laboratories
- MicroVision Pivots: Mapping New Ground Beyond Auto
- Are the Fears Around Alphabet’s Search Slowdown Warranted?
- Streaming Success: Fox Corp Channels Tubi For Q1 Earnings Beat
- Caterpillar’s Sell-Off: Is the Market Missing Its AI Power Play?
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
